Abstract Huanglongbing (HLB) is a destructive citrus disease. The leading cause of HLB is Candidatus Liberibacter asiaticus. Fatty acid biosynthesis（FAS-Ⅱ）is essential for bacterial viability and has been validated as a target for the discovery of novel antibacterials agents. Enoyl−acyl carrier protein reductase (also called ENR or FabI and a product of the fabI gene) is an enzyme required in a critical step of bacterial fatty acid biosynthesis and has attracted attention as a target of novel antimicrobial agents. We determined the crystal structures of FabI from Ca. L. asiaticus in its apo-form as well as in complex with b-nicotinamide adenine dinucleotide (NAD) at 1.7 and 2.7 Å resolutions, respectively, to facilitate the design and screening of small molecule inhibitors of FabI. The monomeric ClFabI is highly similar to other known FabI structures as expected, however, Unlike the typical tetramer, ClFabI exists as hexamer in crystal whereas as dimer in solution, on the other hand, the substrate binding loop which always disordered in apo form, FabI structures is ordered in apo ClFabI. Interestingly, the structure of ClFabI undergoes remarkable conformational change in the substrate-binding loop in the presence of NAD. We conclude that the signature sequence motif of FabI can be considered as Gly-(Xaa) 5 -Ser-(Xaa)n-Val-Tyr-(Xaa) 6 -Lys-(Xaa)n-Thr instead of Tyr-(Xaa) 6 -Lys. We have further identified isoniazid as a competitive inhibitor with NADH. 
Mycobacterium tuberculosis. 15 These homologous structures have been used as models to understand ClFabI in HLB pathogens and to develop new antimicrobial compounds for HLB control.
As a key enzyme in FAS synthesis, FabI is a major target for antimicrobial compounds. FabI assays with varying concentrations of NAD + suggest that NADH oxidation is involved the inhibition reaction; this finding indicates that NAD + facilitates the inhibitory activity of triclosan. 16 Saito et al. 17 elucidated the crystal structure of the enoyl-ACP reductase FabK (isoenzyme of FabI) in Streptococcus pneumoniae and the binding mode of an inhibitor. Rafi et al. 6 showed that complexes are primarily stabilized by interactions with acidic residues in the helix α2 of ACP, illustrating that FabI can serve as a target for drug discovery. 3 Studying on the mechanism of isoniazid inhibit inhA provide significant insight for discovery antimicrobial agent.
Isoniazid has been reported to form isoniazid-NAD adduct, which is a slow, tight-binding co mpetitive inhibitor of InhA from Mycobacterium tuberculosis. 15 To inhibit InhA, isoniazid requires conversion to an activated form of the drug and that a catalase-peroxidase (KatG) participates in isoniazid activation, in its activated form, isoniazid forms covalent attachment with the nicotinamide ring of NAD bound within the active site of InhA. [18] [19] [20] The resulting INH-NAD adducts then inhibits enzyme enoyl-acyl carrier protein reductase (InhA) and thus inhibits mycolic acid biosynthesis. 21 However, the activated form of isoniazid is an intermediate in the formation of isonicotinic acid, isonicotinamide, and pyridine-4-carboxaldehyde, the products of isoniazid oxidation, none of which inhibits
InhA. 22 The structure of INH is simple, but the complex mechanism and target of its inhibitory function remains poorly known. In this study, we attempted to understand whether ClfabI interacts with INH when ClfabI, INH, NAD + , NADH and the substrate crotonoyl coenzyme A are present. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant InhA, the results showed that the limiting rate constant values for NADH dissociation from the isoniazid-resistant InhA-NADH binary complexes. 23 The ENR inhibitor isoniazid (INH) has been used to block enoyl-ACP reductase and thus treats infections efficient of Helicobacter pylori. 24 Synthesis derivatives with side chain of the fatty acid chlorides and alkyl groups as potential enoyl-acyl carrier protein reductase inhibitors exhibit an available means. 25 The structure of INH is simple, but the complex mechanism and target of its inhibitory function remains poorly known. In this study, composed of a parallel beta-sheet with seven strands and flanked by loops and 12 helices, including four 3 10 helices (η1 to η4) (Fig. 1a) . The whole structure could be considered to be prism with three dimers as its sides (Fig. 1b) Table 2 ).
The theoretical molecular weight of CIFabI with 267 aa is 29263.57. Interestingly, a single peak with an elution volume corresponding to a molecular mass of approximately 61.6 kDa is observed in a 120 mL gel filtration on Superdex G200 (25 mM Bis-Tris, pH 6.95, 300 mM NaCl) with respect to a ClFabI dimer (58.5 kDa). The small discrepancy is probably due to extended flexible expression tag at the amino termini of ClFabI. Therefore, we conclude that CIFabI formed stable dimers in solution (Supplement Fig.1 ).
Comparison of apo-ClFabI and ClFabI-NAD binary complexes
There are also six monomers in the ClFabI-NAD binary complex. However, only four indicates that monomer bound with NAD is also similar to the ones of apo-form. The obvious conformational change comes from the region V192-N202, which moves toward NAD after cofactor binding, and the residues T194-S199 in α6 even deviates by more than 5 Å after NAD binding (Fig. 2a) , at the same time the average B-factor of this region in ClFabI-NAD is higher than that in apo ClFabI (71.2 in ClFabI-NAD and 40.3 in apo form)
The electron density map clearly reveals the position of the cofactor without any ambiguity and the residues S20, I21, N65, A94, K163, V192, T194, and A196 are involved in the interaction with NAD (Fig. 2b) . The adenosine moiety interplays with side-chain atoms of Q41 and N65, and main-chain atoms of G14 and V66, whereas the pyrophosphate moiety forms hydrogen bonds with side-chain oxygen atom of S20 and main-chain nitrogen atoms of I21 and A196. The nicotinamide ribose moiety is bounded by K163, V192, and T194. Aside from these residues, five water atoms also form hydrogen bonds with NAD. The final refinement statistics are summarized in Table 1 .
Structural comparison of ClFabI with other ENR structures
The topology of the ClFabI monomer is similar to those of other ENRs from different species and the results of structure-based Dali search 27 showed hundreds of homologous structures. In the present study, homologous structures from the top nine species are selected to compare Although the loop occupies various positions in different species in binary complexes, it only has a closed conformation in the FabI-cofactor-inhibitor ternary complex and has lower average B-factor than in binary complexes, for example, the average B-factors of it in Thermus thermophiles FabI (TtFabI, PDB code 2wyw), Escherichia coli FabI (EcFabI, PDB code 1c14) and Helicobacter pylori FabI (HpFabI, PDB code 2pd3) are 27.8, 43.2 and 48.6, respectively. Therefore, the loop is flexible until it is hold by hydrogen bonds with a cofactor and inhibitor or substrate and its flexibility can be used to design new antimicrobial regent.
Conversely, the average B-factor of NAD in the binary complexes was higher than that of the protein. Moreover, NAD did not occupy all monomers in the binary complexes. For instance, 6 -Lys-(Xaa) n -Thr.
Inhibition of ClFabI enzyme activity in Ca. L. by INH
The inhibitory mechanism of INH was investigated using the enzyme kinetic method. The inhibitory activity percentages corresponding to NADH were 29.7%, 45.6%, and 70.6%, the correlation coefficient corresponding to the inhibitor concentration was 0.9765, and the inhibitory activity percentages corresponding to crotonoyl-CoA were 10%, 36.7%, and 48.9%. Table 3 ).
In respectively, and the cofactor positions were nearly identical. Therefore, it is reasonable to speculate that IMJ should lie at a similar position in the ClFabI ternary structure (Fig. 4) In summary, the crystal study of CIFabI has special significance for screening of antibacterial agents against HLB in citrus with structure-based strategies. We determined the apo ClFabI and ClFabI-NAD binary crystal structures, which are both six monomers in one ASU in crystal. They both exist as dimer in solution, and all the disordered residues in apo FabI crystals from other species are ordered in our apo structure. Based on sequence alignment and residues involved in hydrogen bond network of FabIs, the signature sequence motif is expanded from Tyr-(Xaa) 6 -Lys to Gly-(Xaa) 5 -Ser-(Xaa) n -Val-Tyr-(Xaa) 6 -Lys-(Xaa) n -Thr.
The resulting structure information regarding the active site pocket and details of the NAD + binding mode could be used as bases for the rational design of more effective FabI inhibitors against Candidatus Liberibacter.
We suggest that the crystal structure of complexes of other new inhibitors and ClfabI in Ca. L.
should be performed in the future. At present, the kinetics analysis is primary and 
Material and Methods

Cloning, expression, and purification
The ClFabI gene was amplified from the genomic DNA (NC_012985) of Ca. L. asiaticus and was inserted into the pET28a-SOMU1 expression vector (constructed based on pET28a by our lab). The construct was transformed into BL21 (DE3) for expression. Cells were grown in Luria−Bertani medium supplemented with 50 mg/mL kanamycin at 37°C until an OD 600 value of 0.6 to 0.8 was reached. IPTG was added to a final concentration of 0.4 mM to induce expression at 16°C for 20 h. The cell pellet was harvested, resuspended in ice-cold lysis buffer a (25 mM Bis−Tris, pH 6.95, 400 mM NaCl, 2 mM 2-mercaptoethanol), and then subjected to French press (JN3000 PLUS). The supernatant was collected after centrifugation at 16, 000 rpm (Sorvall GSA rotor) for 55 min at 4°C.
The supernatant was loaded onto a Ni 2+ Hi-Trap chelating column (Amersham Biosciences), washed with 70 mM imidazole in buffer B (25 mM Bis-tris, pH 6.95, 1 M NaCl), and then eluted with 500 mM imidazole in buffer B. The SUMO tag was enzymatically cleaved overnight at 4°C by SUMO protease (ULP1), and the target protein was isolated by a second Ni affinity chromatography step. After concentration, the protein sample was further purified using a Superdex™ 200 (GE healthcare) column equilibrated with buffer C (25mM Bis-Tris, pH 6.95, 300 mM NaCl) at 4°C in an AKTA system (Amersham Bioscience). The molecular weight of purified CLFabI protein in solution was calibrated according to a 120 mL Superdex™ 200 column in AKTA.
Crystallization and X-ray data collection
Crystallization of ClFabI was screened by the sitting-drop vapor-diffusion method at 4 and 20°C. The protein was concentrated to 15 mg/mL in 25mM Bis-Tris, pH 6.95, 300 mM NaCl 
Structure determination and refinement
The crystal structure of ClFabI in the apo-form (PDB ID coed: 4NK4) is determined by molecular replacement using Phaser. 33 The crystal structure of short-chain dehydrogenase reductase glucose-ribitol dehydrogenase from Brucella melitensis (PDB code: 3GRK) is used as the search model. According to the Matthews coefficient, we estimate six, seven, or eight molecules in the asymmetric unit (ASU), with solvent constants of 54.8%, 47.3%, or 39.7%, respectively. Given that 3GRK containe eight molecules. The dimer (chains B and D) is adopted, and the high value of TFZ suggest that ASU containe six molecules. The binary complex structure is determined by molecular replacement using the apo-form structure as the search model. Manual rebuilding is performed by operating Coot, 38 and refinement is carried out by applying Phenix. Refine. 39 Final models are validated by adopting MolProbity, 40 and all structure figures are generated utilizing pymol (http://www.pymol.org/).
ClFabI inhibition assays
The catalytic activity of ClFabI that reduced enoyl-ACP coupled with the concomitant oxidation of NADH was assayed based on a modified protocol. 8, 41 INH, NADH, crotonoyl-CoA, and dimethyl sulfoxide (DMSO) were purchased from Sigma (USA). All Note: the number in parenthesis indicates the corresponding residue number in ClFabI. *Only one monomer in 3GNS and 3OJE, the dimer is generated by crystal symmetry, so the residues contained in dimer interaction is also symmetric. 
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